Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.
Armandola
Elena
E
European Patent Office, Munich, Germany.
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000818:Animals; D004279:DNA, Viral / Q000627:therapeutic use; D046129:Ebola Vaccines / Q000627:therapeutic use*; D029043:Ebolavirus / Q000276:immunology* / Q000472:pathogenicity; D015686:Gene Products, env / Q000627:therapeutic use; D015683:Gene Products, gag / Q000627:therapeutic use; D015696:Gene Products, tat / Q000627:therapeutic use; D006678:HIV / Q000276:immunology* / Q000472:pathogenicity; D015658:HIV Infections / Q000517:prevention & control; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control; D006801:Humans; D016882:ISCOMs / Q000627:therapeutic use; D007111:Immunity, Cellular / Q000502:physiology; D018928:Immunity, Mucosal / Q000502:physiology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology / Q000472:pathogenicity; D045169:Severe Acute Respiratory Syndrome / Q000517:prevention & control; D013030:Spain; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology; D019444:Vaccines, DNA / Q000627:therapeutic use; D054322:tat Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D004279:DNA, Viral; D046129:Ebola Vaccines; D015686:Gene Products, env; D015683:Gene Products, gag; D015696:Gene Products, tat; D016882:ISCOMs; D019444:Vaccines, DNA; D054322:tat Gene Products, Human Immunodeficiency Virus